À retenir
In a meta-analysis of prospective studies, people with sarcopenia had higher odds of death (pooled OR 3.596, 95% CI 2.96-4.37) and of functional decline (pooled OR 3.03, 95% CI 1.80-5.12). Most outcomes besides mortality rest on very few studies, so those results are less certain.
Study design
Revue des preuves
Reading basis
Published abstract
Reading focus
Design & applicability
Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.
Question de recherche
Sarcopenia, the loss of muscle mass and function with age, is thought to harm health, but the short-, middle- and long-term consequences had not been summarised. The authors reviewed prospective studies to assess what happens to people diagnosed with it.
Population et méthode
Systematic review with meta-analysis of prospective studies, searched across MEDLINE, EMBASE, EBM Reviews, the Cochrane Database of Systematic Reviews, ACP Journal Club, DARE and AMED. Only studies that diagnosed sarcopenia using the European Working Group on Sarcopenia in Older People definition were included. Two independent reviewers did selection and extraction. A meta-analysis was done for outcomes reported by three or more studies, expressed as odds ratios (OR) with 95% CI. Of 772 references, 17 studies were included, with 99 to 6658 participants and follow-up from 3 months to 9.8 years.
Résultats
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Eleven of 12 studies that assessed mortality found a higher death rate in people with sarcopenia, with a pooled OR of 3.596 (95% CI 2.96-4.37). The effect was larger in people aged 79 years or older than in younger subjects (p = 0.02).
- 2Sarcopenia was associated with functional decline, with a pooled OR across 6 studies of 3.03 (95% CI 1.80-5.12).
- 3Falls were associated with sarcopenia in 2 of 2 studies, and hospitalization in 1 of 1 study.
- 4The effect on fractures and length of hospital stay was less clear, with only 1 of 2 studies showing an association for each.
Limites et incertitude
- 1Falls, hospitalization, fractures and length of stay rest on one or two studies each, so they cannot be pooled or judged reliably.
- 2The included studies were of varying size (99 to 6658 participants) and follow-up (3 months to 9.8 years), which the abstract does not say was handled in the pooled estimate.
- 3An odds ratio of 3.596 compares odds, not absolute risk, and the abstract does not give baseline death rates; sarcopenic people may also differ in other ways, such as frailty or illness.
- 4This reading is based on the abstract only.
Mise en perspective
Low muscle mass and function in older age goes with substantially worse outcomes, especially death and loss of everyday function. This review does not show that building muscle changes those outcomes. Anyone worried about muscle loss, falls or weakness should talk with their clinician.
Vos données
Sarcopenia is diagnosed with measures of muscle mass, strength and physical performance, not by a wearable. Body weight alone cannot show it, but grip strength tests, chair-stand times, walking speed and strength-training logs followed over months on the same equipment give a more useful personal picture.
Comprendre ce type de preuve
Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.
Résumé structuré des auteurs English
Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.
Objective
The purpose of this study was to perform a systematic review to assess the short-, middle- and long-term consequences of sarcopenia.
Methods
Prospective studies assessing the consequences of sarcopenia were searched across different electronic databases (MEDLINE, EMBASE, EBM Reviews, Cochrane Database of Systematic Reviews, EBM Reviews ACP Journal Club, EBM Reviews DARE and AMED). Only studies that used the definition of the European Working Group on Sarcopenia in Older People to diagnose sarcopenia were included. Study selection and data extraction were performed by two independent reviewers. For outcomes reported by three or more studies, a meta-analysis was performed. The study results are expressed as odds ratios (OR) with 95% CI.
Results
Of the 772 references identified through the database search, 17 were included in this systematic review. The number of participants in the included studies ranged from 99 to 6658, and the duration of follow-up varied from 3 months to 9.8 years. Eleven out of 12 studies assessed the impact of sarcopenia on mortality. The results showed a higher rate of mortality among sarcopenic subjects (pooled OR of 3.596 (95% CI 2.96-4.37)). The effect was higher in people aged 79 years or older compared with younger subjects (p = 0.02). Sarcopenia is also associated with functional decline (pooled OR of 6 studies 3.03 (95% CI 1.80-5.12)), a higher rate of falls (2/2 studies found a significant association) and a higher incidence of hospitalizations (1/1 study). The impact of sarcopenia on the incidence of fractures and the length of hospital stay was less clear (only 1/2 studies showed an association for both outcomes).
Conclusion
Sarcopenia is associated with several harmful outcomes, making this geriatric syndrome a real public health burden.
Sources et attribution
Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis.
Beaudart C, Zaaria M, Pasleau F, Reginster JY, Bruyère O.
PloS one · 2017-01-17
DOI: 10.1371/journal.pone.0169548 ↗PubMed · 28095426 ↗Europe PMC · Licence indiquée: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée
Sources vérifiées 2026-11-01
Guides pratiques
À lire ensemble
ACSM review of 137 reviews: resistance training works, and few programme details matter
The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.
Medicine & Science in Sports & Exercise
Nearly every resistance training plan beat no exercise; heavy loads led for strength
In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.
British Journal of Sports Medicine
Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes
Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.
British Journal of Sports Medicine
Protein supplements and weight training: small extra gains, smaller in older adults
Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.
British Journal of Sports Medicine

